Skip to content

Study · Non-randomized trial · n = 12 · 1988

6 results

Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995.

Hopman WP, Wolberink RG, Lamers CB, Van Tongeren JH

Annals of surgery1 Feb 1988Cited by 52 (Europe PMC)

PMID2893592 (opens in a new tab)DOI10.1097/00000658-198802000-00007 (opens in a new tab)PepBankPUB-02893592
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In early and late dumping, octreotide improved postprandial breath hydrogen excretion versus placebo, indicating slower gastrointestinal transit.

    In plain wordsIn early and late dumping, octreotide improved breath hydrogen measurements versus placebo, indicating slower gut transit.

    Peptide
    Octreotide
    Outcome
    Direction not reportedPostprandial breath hydrogen excretion
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    50 microgramsAs given in this study (human).

    Source sentences

    Summary
    Both in early and late dumpers SMS 201-995 improved postprandial expiratory breath hydrogen excretion indicating slowing of gastrointestinal hurry.
    1 context sentence
    Summary · context
    In six patients suffering from severe early dumping and six patients with late dumping after peptic ulcer surgery, the effect of the somatostatin analogue SMS 201-995 was compared with placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In early dumping, octreotide reduced Sigstad score from 12 +/- 2 with placebo to 5 +/- 2 (p less than 0.05).

    In plain wordsIn early dumping, octreotide reduced symptom scores versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseEarly dumping symptoms
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    50 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Sigstad dumping score
    12 score
    placebo, early dumpers; +/- 2
    Sigstad dumping score
    5 score
    SMS 201-995 50 micrograms sc, early dumpers; +/- 2

    Source sentences

    Summary
    In early dumpers subcutaneous administration of 50 micrograms SMS 201-995 prior to meal ingestion induced a strong improvement of dumping symptoms as reflected by a decrease of the Sigstad dumping score from 12 +/- 2 during placebo to 5 +/- 2 (p less than 0.05).
    1 context sentence
    Summary · context
    In six patients suffering from severe early dumping and six patients with late dumping after peptic ulcer surgery, the effect of the somatostatin analogue SMS 201-995 was compared with placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In early dumping, octreotide reduced maximum pulse rate from 85 +/- 7 to 67 +/- 7 beats/min versus placebo (p less than 0.05).

    In plain wordsIn early dumping, octreotide reduced the maximum pulse rate after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMaximum postprandial pulse rate
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    50 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Maximum postprandial pulse rate
    85 beats/min
    starting value of reported decrease, early dumpers; +/- 7
    Maximum postprandial pulse rate
    67 beats/min
    with SMS 201-995, early dumpers; +/- 7

    Source sentences

    Summary
    Furthermore, the postprandial increase of pulse rate was abolished; maximum pulse rate decreased from 85 +/- 7 beats/min to 67 +/- 7 beats/min (p less than 0.05).
    2 context sentences
    Summary · context
    In early dumpers subcutaneous administration of 50 micrograms SMS 201-995 prior to meal ingestion induced a strong improvement of dumping symptoms as reflected by a decrease of the Sigstad dumping score from 12 +/- 2 during placebo to 5 +/- 2 (p less than 0.05).
    Summary · context
    In six patients suffering from severe early dumping and six patients with late dumping after peptic ulcer surgery, the effect of the somatostatin analogue SMS 201-995 was compared with placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In early dumping, octreotide did not significantly affect postprandial packed cell volume changes versus placebo.

    In plain wordsIn early dumping, octreotide did not significantly change packed blood cell volume after food versus placebo.

    Peptide
    Octreotide
    Outcome
    No significant changePostprandial packed cell volume
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Blood volume · Cardiovascular
    Studied dose
    50 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    SMS 201-995 did not significantly affect postprandial changes in packed cell volume.
    1 context sentence
    Summary · context
    In six patients suffering from severe early dumping and six patients with late dumping after peptic ulcer surgery, the effect of the somatostatin analogue SMS 201-995 was compared with placebo.
  5. 05HumanNon-randomized trialEfficacy outcome

    In late dumping, octreotide reduced peak insulin from 173 +/- 16 with placebo to 35 +/- 9 mU/L (p less than 0.05).

    In plain wordsIn late dumping, octreotide reduced peak insulin after oral glucose versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePeak insulin after glucose
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 microgramsAs given in this study (human).

    Measurements

    Peak plasma insulin after oral glucose
    173 mU/L
    placebo, late dumpers; +/- 16
    Peak plasma insulin after oral glucose
    35 mU/L
    SMS 201-995 50 micrograms, late dumpers; +/- 9

    Source sentences

    Summary
    In late dumpers 50 micrograms SMS 201-995 reduced peak plasma insulin after oral glucose from 173 +/- 16 mU/L during placebo to 35 +/- 9 mU/L during SMS 201-995 (p less than 0.05) and increased individual plasma glucose nadirs from 1.9 +/- 0.3 mmol/L to 7.5 +/- 3.3 mmol/L (p less than 0.01).
    1 context sentence
    Summary · context
    In six patients suffering from severe early dumping and six patients with late dumping after peptic ulcer surgery, the effect of the somatostatin analogue SMS 201-995 was compared with placebo.
  6. 06HumanNon-randomized trialEfficacy outcome

    In late dumping, octreotide increased plasma glucose nadirs from 1.9 +/- 0.3 to 7.5 +/- 3.3 mmol/L versus placebo (p less than 0.01).

    In plain wordsIn late dumping, octreotide increased the lowest blood sugar after oral glucose versus placebo.

    Peptide
    Octreotide
    Outcome
    IncreaseGlucose nadir after glucose
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 microgramsAs given in this study (human).

    Measurements

    Individual plasma glucose nadir
    1.9 mmol/L
    starting value, late dumpers; +/- 0.3
    Individual plasma glucose nadir
    7.5 mmol/L
    with SMS 201-995 50 micrograms, late dumpers; +/- 3.3

    Source sentences

    Summary
    In late dumpers 50 micrograms SMS 201-995 reduced peak plasma insulin after oral glucose from 173 +/- 16 mU/L during placebo to 35 +/- 9 mU/L during SMS 201-995 (p less than 0.05) and increased individual plasma glucose nadirs from 1.9 +/- 0.3 mmol/L to 7.5 +/- 3.3 mmol/L (p less than 0.01).
    1 context sentence
    Summary · context
    In six patients suffering from severe early dumping and six patients with late dumping after peptic ulcer surgery, the effect of the somatostatin analogue SMS 201-995 was compared with placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.